Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 12, 2020- IKEMA trial results released early based on recommendation of an Independent Data Monitoring Committee
-
May 7, 2020- Company on Track to Complete Submission of Rolling Biologics License Application for Teplizumab in Q4 2020 -
-
May 5, 2020Objective responses seen in 29% of patients with locally advanced basal cell carcinoma (BCC)
-
Apr 27, 2020- Libtayo decreased the risk of death by 32.4% compared to chemotherapy
-
Apr 27, 2020• Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group
-
Apr 24, 2020Latest innovation in quadrivalent meningococcal vaccination designed for use in persons 2 years of age and older in the U.S.
-
Apr 23, 2020Primary and secondary objectives were met with 85% or greater relative reduction achieved in the number of new gadolinium-enhancing T1 and new or enlarging T2 hyperintense lesions
-
Apr 16, 2020- Companies to negotiate a collaboration on the development of a breakthrough COVID-19 self-test solution based on Luminostics’ proprietary technology.
